+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Harrow Inc (HROW) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 48 Pages
  • October 2024
  • GlobalData
  • ID: 4319042
Harrow Inc (HROW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Harrow Inc (Harrow) is a leading pharmaceutical company specializing in the ophthalmic healthcare sector. The company's primary activities involve the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products. Harrow's product portfolio includes a wide range of FDA-approved prescription and non-prescription pharmaceuticals for treating various eye conditions, such as dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. The company markets its products under the Harrow name and also operates ImprimisRx, a leading ophthalmology-focused pharmaceutical-compounding business. Harrow's products are used by doctors, hospitals, and ambulatory surgical centers (ASCs) across various industries. The company operates across the US. Harrow is headquartered in Nashville, Tennessee, the US.

Harrow Inc Key Recent Developments

  • Jul 12, 2024: Harrow to Attend 2024 ASRS Annual Meeting
  • May 13, 2024: Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
  • Mar 19, 2024: Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
  • Mar 05, 2024: Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Harrow Inc - Key Facts
  • Harrow Inc - Key Employees
  • Harrow Inc - Key Employee Biographies
  • Harrow Inc - Major Products and Services
  • Harrow Inc - History
  • Harrow Inc - Company Statement
  • Harrow Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Harrow Inc - Business Description
  • R&D Overview
  • Harrow Inc - Corporate Strategy
  • Harrow Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Harrow Inc - Strengths
  • Harrow Inc - Weaknesses
  • Harrow Inc - Opportunities
  • Harrow Inc - Threats
  • Harrow Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Harrow Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jul 12, 2024: Harrow to Attend 2024 ASRS Annual Meeting
  • May 13, 2024: Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
  • Mar 19, 2024: Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
  • Mar 05, 2024: Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19 2024
  • Jan 29, 2024: Harrow Announces New Appointments to its Board of Directors
  • May 11, 2023: Harrow Announces First Quarter 2023 Financial Results
  • May 02, 2023: Harrow launches ILEVRO, NEVANAC, and MAXIDEX in the U.S.
  • Mar 23, 2023: Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
  • Feb 15, 2023: Harrow launches next-generation compounded atropine formulations
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Harrow Inc, Key Facts
  • Harrow Inc, Key Employees
  • Harrow Inc, Key Employee Biographies
  • Harrow Inc, Major Products and Services
  • Harrow Inc, History
  • Harrow Inc, Subsidiaries
  • Harrow Inc, Key Competitors
  • Harrow Inc, Ratios based on current share price
  • Harrow Inc, Annual Ratios
  • Harrow Inc, Interim Ratios
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Harrow Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Harrow Inc, Performance Chart (2019 - 2023)
  • Harrow Inc, Ratio Charts
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Harrow Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Omeros Corp
  • Chethana Pharmaceuticals
  • Casper Pharma LLC
  • Bausch & Lomb Inc